(Alliance News) - Horizon Discovery Group PLC on Tuesday said it is offering its Chosource platform under special commercial licensing terms in order to develop treatments and tests for Covid-19.
Chosource is already offered by gene editing firm Horizon "as a royalty-free alternative for the production of complex proteins" and has been used for "multiple successful Innovative New Drug filings".
Under the new special licencing terms, companies developing "therapeutic proteins, diagnostic assay components or vaccines relating to Covid-19" will have rapid access to Chosource, letting them streamline the production and development of therapies.
Horizon said Chosource includes a gene-edited cell line which has been recognised as "suitable for high yield biomanufacturing." by both regulators and the industry.
Chief Executive Terry Pizzie said: "We are committed to providing flexible, royalty-free access licensing terms and solutions that streamline development and production processes. Building upon more than a decade of experience in cell line engineering, we developed our Chosource cell line and now support a growing number of pharmaceutical companies in bioproduction. We are doing all that we can to support the fight against Covid-19 and hope that offering rapid access to our Chosource platform will help to accelerate the development and validation of new therapies to combat the pandemic."
Shares in Horizon were down 1.2% at 126.50 pence in London on Wednesday.
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
